PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy
Premium
While the results are from a small study, investigators are working to validate them in larger groups, hoping their method can prove itself for clinical use.Â
Lunit Gets CE Mark for AI-Based PD-L1 Expression Test
The South Korean biotech company plans to launch the Lunit Scope PD-L1 test in Europe in the second half of this year.
Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study
Premium
The company published a pilot study showing that it's five-miRNA signature could predict which lung cancer patients survived longer on immunotherapy treatment.
Agilent Expands CE-IVD Mark for Companion Dx Tests Alongside BMS European Opdivo Approvals
Agilent obtained a CE-IVD mark for expanded use of its PD-L1 IHC 28-8 pharmDx assay to guide cancer treatment with Bristol Myers Squibb's Opdivo.
Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis
Under the collaboration, Roche is developing an artificial intelligence-based image analysis algorithm to help pathologists interpret its Ventana PD-L1 (SP142) Assay.